Case report: Ustekinumab for Crohn's continued in pregnancy

Case report: ustekinumab for crohn's continued in pregnancy

(HealthDay)—Good outcome has been reported in a pregnant woman who continued ustekinumab (UST) therapy for Crohn's disease during pregnancy, according to a case report published online Dec. 22 in the Journal of Clinical Pharmacy and Therapeutics.

Xavier Cortes, M.D., from the Hospital de Sagunto in Spain, and colleagues describe the case of a with Crohn's disease who was successfully treated with UST maintenance therapy during pregnancy. The 37-year-old patient had been receiving UST for eight months before becoming pregnant. She continued UST treatment after discussion with the obstetric team.

The authors note that the patient had an uneventful pregnancy and delivered a healthy baby boy at term. The patient was in clinical and biological remission during pregnancy and was still in clinical, biological, and endoscopic remission six months after delivery. No side effects were reported during UST therapy, with no recurrent episodes and no reports of problems for the baby at one-year follow-up.

"To our knowledge, this is the first reported use of continued UST therapy for Crohn's disease throughout a pregnancy," the authors write. "The result of treatment was an uncomplicated pregnancy with the mother giving birth to a healthy boy at term and the maintenance of clinical biological and endoscopic remission of Crohn's disease during and after pregnancy."


Explore further

Smoking while pregnant may compromise children's kidney function

More information: Full Text (subscription or payment may be required)

Copyright © 2016 HealthDay. All rights reserved.

Citation: Case report: Ustekinumab for Crohn's continued in pregnancy (2016, December 28) retrieved 6 July 2020 from https://medicalxpress.com/news/2016-12-case-ustekinumab-crohn-pregnancy.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
1 shares

Feedback to editors

User comments